| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 500mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
14:0 PEG-PE does not have a specific biological target. It is a lipid-polymer conjugate used as a formulation excipient for drug delivery. The 14:0 fatty acid tail facilitates membrane integration, while the PEG chain helps reduce immune recognition and prolongs circulation time in vivo. This makes it an effective component in targeted delivery and controlled-release therapies.
|
|---|---|
| ln Vitro |
In vitro, 14:0 PEG-PE is used to formulate lipid nanoparticles for drug delivery. Its presence in formulations can enhance stability and reduce protein adsorption. Specific activity data are not applicable as it is not a pharmacologically active drug.
|
| ln Vivo |
In vivo, 14:0 PEG-PE is used to formulate lipid-based drug delivery systems. The PEG chain prolongs circulation time and reduces immune recognition, which can improve the pharmacokinetics and biodistribution of encapsulated drugs. It is used in the preparation of nanostructured lipid carriers.
|
| Enzyme Assay |
A cell-free assay for 14:0 PEG-PE is not applicable as it is not a pharmacologically active compound. Its properties are characterized by physical methods, such as dynamic light scattering and zeta potential measurement.
|
| Cell Assay |
Cellular experiments with 14:0 PEG-PE typically involve evaluating the uptake and biocompatibility of lipid nanoparticles containing the compound. The compound is used as a formulation component rather than an active agent. Specific protocols depend on the encapsulated drug.
|
| Animal Protocol |
In vivo animal experiments using 14:0 PEG-PE typically involve the administration of lipid-based formulations containing the compound. Specific protocols depend on the therapeutic payload and disease model.
|
| ADME/Pharmacokinetics |
14:0 PEG-PE is a formulation excipient and does not have conventional pharmacokinetic properties as a pharmacologically active drug. Its role is to modify the PK of encapsulated drugs by prolonging circulation time.
|
| Toxicity/Toxicokinetics |
14:0 PEG-PE is generally considered non-toxic and is used in pharmaceutical and biomedical research. However, specific toxicity data are not provided. It is intended for research use and is not for direct human consumption as a standalone agent.
|
| References | |
| Additional Infomation |
14:0 PEG-PE (CAS: 474922-82-2) is a PEG-phospholipid conjugate used in the preparation of lipid nanoparticles for drug delivery. It consists of a 14-carbon fatty acid tail, a PEG chain, and a PE headgroup. The compound is used to form liposomes and nanostructured lipid carriers. Its molecular formula is C37H75N2O11P. It is not a therapeutic drug itself but a critical excipient in drug delivery systems.
|
| Molecular Weight |
754.971973657608
|
|---|---|
| Exact Mass |
754.51
|
| CAS # |
474922-82-2
|
| Related CAS # |
474922-82-2
|
| PubChem CID |
156594148
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
40
|
| Heavy Atom Count |
51
|
| Complexity |
861
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
P(=O)(O)(OCCNC(=O)OCCOC)OCC(COC(CCCCCCCCCCCCC)=O)OC(CCCCCCCCCCCCC)=O.N
|
| InChi Key |
DJYTWZDTQHDVBC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C37H72NO11P.H3N/c1-4-6-8-10-12-14-16-18-20-22-24-26-35(39)46-32-34(33-48-50(42,43)47-29-28-38-37(41)45-31-30-44-3)49-36(40)27-25-23-21-19-17-15-13-11-9-7-5-2;/h34H,4-33H2,1-3H3,(H,38,41)(H,42,43);1H3
|
| Chemical Name |
azane;[3-[hydroxy-[2-(2-methoxyethoxycarbonylamino)ethoxy]phosphoryl]oxy-2-tetradecanoyloxypropyl] tetradecanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3246 mL | 6.6228 mL | 13.2456 mL | |
| 5 mM | 0.2649 mL | 1.3246 mL | 2.6491 mL | |
| 10 mM | 0.1325 mL | 0.6623 mL | 1.3246 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
